About Erkan Hassan, PharmD

Erkan has over 20 years’ experience solving clinical challenges and improving patient-centered outcomes by using evidence-based clinical data to create innovative, intelligent healthcare systems. This consists of proactive clinical surveillance, streamlining workflows, measuring and reporting outcomes.

Changes in Sepsis Trends: Real or Artificial

By |2022-02-15T07:40:32+00:00January 31st, 2022|Sepsis|

Changes in Sepsis Trends: Real or Artificial? SUMMARY Recent reports indicate a significant increase in the incidence of sepsis with a concomitant drop in mortality. Controversy exists over the true degree of change based on changing definitions and coding practices. Direct clinical indicators of infection and organ dysfunction are preferred

Use of Steroids in Sepsis

By |2022-01-11T10:32:24+00:00January 11th, 2022|Sepsis|

Use of Steroids in Sepsis SUMMARY The use of corticosteroids in sepsis has been recommended on and off for over 40 years. The Surviving Sepsis Campaign (SSC) guidelines previously (2016) did not support steroid use in patients with sepsis, however, the current (2021) recommendation the use of steroids in certain septic shock

3 Major Lactate Considerations in Sepsis

By |2021-11-23T07:14:43+00:00November 23rd, 2021|Sepsis|

3 Major Lactate Considerations in Sepsis SUMMARY Serum lactate measurements have been part of the sepsis bundles since the beginning. The recommendation to use and follow serum lactate concentrations are based on weak and low-quality evidence. Changes in serum lactate concentrations are not solely reflective of changes in production but also based

Surviving Sepsis Campaign Guidelines

By |2021-11-09T09:27:34+00:00November 9th, 2021|Sepsis|

Should Hemodynamic Profiling be a Sepsis Best Practice? SUMMARY Surviving Sepsis Campaign (SSC) guidelines were previously developed in 2016 and published in 2017. The SSC 2021 guidelines provides an update to the SSC 2016 guidelines. New recommendations are provided for a number of areas in the management of sepsis.

Should Hemodynamic Profiling be a Sepsis Best Practice?

By |2021-10-18T07:35:40+00:00October 18th, 2021|Sepsis|

Should Hemodynamic Profiling be a Sepsis Best Practice? SUMMARY Hemodynamic profiles in critically ill patients are complex and change over the sepsis course. Macro-circulatory and micro-circulatory factors contribute equally to the evolving disease state. During the later stages of hemodynamic impairment, both factors must be considered. BACKGROUNDIn addition to

Sepsis Associated Encephalopathy (SAE)

By |2021-09-21T03:43:48+00:00September 21st, 2021|Sepsis|

Sepsis Associated Encephalopathy (SAE) SUMMARYSAE is a key manifestation of sepsis occurring in up to 70% of ICU patientsAssociated with higher ICU and hospital mortality and long term consequencesDifficult to assess, diagnose without specific treatment BACKGROUNDSAE is probably the most common type of encephalopathy in the ICUSAE may occur

Is the Mortality Rate from Sepsis Improving?

By |2021-08-25T08:55:11+00:00August 25th, 2021|Sepsis|

Is the Mortality Rate from Sepsis Improving? SUMMARY The true incidence of sepsis is difficult to define. Sepsis cases are not evenly distributed Despite global efforts on improved recognition and management, the overall sepsis mortality rate has been stable. Sub-segments of the population may be experiencing increasing mortality rates. BACKGROUND

What Truly Defines Organ Dysfunction Due to Sepsis?

By |2021-08-09T06:40:35+00:00August 9th, 2021|Sepsis|

How Should We Screen for Sepsis? SUMMARY Organ dysfunction is one of the defining characteristics in the current definition of sepsis. Many of the markers currently in use are nonspecific. Organ dysfunction and injury are separate processes that need to be differentiated. Understanding ways dysfunction can be better detected will

How Should We Screen for Sepsis?

By |2021-07-26T08:49:55+00:00July 26th, 2021|Sepsis|

How Should We Screen for Sepsis? SUMMARY Sepsis screening remains a major challenge, especially in varied settings. Effective screening impacts treatment, quality of care initiatives and outcomes. Different screening tools may be needed based on the clinical setting. The tool at each site may need to be tuned uniquely for that population

Go to Top